Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2019 17:01 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics’ Preclinical Data Demonstrate its alphalex™ Platform Enables Tumor Targeting of Multiple PARP Inhibitors, Effectively Inducing Significant Tumor Cell Killing When Combined with Chemotherapy

Results support the potential of alphalex™ technology with diverse range of anticancer agents Targets HRD-negative cancers, while avoiding significant bone marrow toxicity typically induced when PARP...
April 02, 2019 08:00 ET | Source: Cybrexa Therapeutics

Cybrexa Therapeutics Unveils Rucaparib as FDA- and EMA-Approved PARP Inhibitor in Lead Candidate CBX-11, Which Demonstrates Synergistic Efficacy with Chemotherapy Without Compounded Toxicity

Tumor-selective CBX-11 allows full dose co-administration with chemotherapy, enabling synergistic efficacy in HRD negative tumors Poster presentation today during AACR Annual Meeting 2019 ...